Previous Frame Next Frame
  • Discover: How Intrexon
    is creating the code for a
    healthier planet

    World Demand
  • Intrexon Energy Partners to
    Generate High-value Oil Products
    from Low-Cost Natural Gas

    DISCOVER

    Intrexon Energy Partners to Generate High-value Oil Products from Low-Cost Natural Gas
  • Optimizing therapeutics production:
    Improving the way we generate active pharmaceutical ingredients

    DISCOVER

    Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Intrexon and Johnson & Johnson to
    advance new hair and skin products

    DISCOVER

    Johnson & Johnson Innovation
  • Next-generation fertility solutions

    DISCOVER

    OvaScience
  • World Demand
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Johnson & Johnson Innovation
  • OvaScience

UltraVector® platform to power the next generation of bio-based products
LEAP® automated purification of high value cells
RheoSwitch® precisely controlled expression
IN THE SPOTLIGHT
HEALTH
Collaboration:
Ziopharm and Intrexon are on the path to treating melanoma
FOOD
Extreme Weather:
Drought and the need for novel food applications
ENERGY
Engineering Energy:
Fueling the world with microbes
LATEST NEWS
Histogenics and Intrexon Announce Formation of Exclusive Channel Collaboration for Cartilage Repair Therapies
Companies to Develop Universal Donor Chondrocyte Cell Treatments WALTHAM, Mass. and GERMANTOWN, Md., Oct. 3, 2014 /PRNewswire/ -- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of an Exclusive Channel Collaboration (ECC) for the generation of allogeneic chondrocyte cell therapeutics to repair damaged articular hyaline cartilage in humans.   "We are pleased to enter into this strategic partnership and are excited by the opportunity to couple Intrexon's market-leading expertise in synthetic biology ...
Intrexon and Amneal Expand Relationship with Second Product Collaboration
Companies to Utilize Intrexon's Novel Microbial-based Production Approach for a Target Active Pharmaceutical Ingredient SAN CARLOS, Calif. and BRIDGEWATER, N.J., Oct. 2, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Amneal Pharmaceuticals LLC, the seventh largest generic drug manufacturer by volume in the U.S., today announced the formation of a second Exclusive Channel Collaboration (ECC) for a target active pharmaceutical ingredient (API).  Utilizing Intrexon's robust microbial-based expression system, the goal of the collaboration is to develop a consistent, scalable, and cost-effective process for the targeted complex API. "The power o...
Fibrocell Science and Intrexon Advance GM-HDF-COL7 toward Clinical Development for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
- IND Filing Planned for 1H 2015 - - Genetically-Modified Autologous Cell Therapy Potential First-in-Class Treatment for RDEB - EXTON, PA and GERMANTOWN, MD – September 24, 2014 – Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) in the first half of 2015 for their drug candidate, GM-HDF-COL7 (genetically-modified human dermal fibroblast, collagen VII). The ...